

Vlad Ratziu

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3856547/vlad-ratziu-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

153
papers

11,807
citations

49
h-index

107
g-index

192
ext. papers

17,019
ext. citations

7.7
avg, IF

6.52
L-index

#	Paper	IF	Citations
153	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD.. <i>Journal of Hepatology</i> , 2022 ,	13.4	5
152	Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery.. <i>Hepatology</i> , 2022 ,	11.2	2
151	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , 2022 , 4, 100409	10.3	4
150	Reply to Jindal et al.. <i>Hepatology</i> , 2022 ,	11.2	
149	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19.. <i>Biomedicines</i> , 2022 , 10,	4.8	1
148	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. <i>JHEP Reports</i> , 2022 , 4, 100477	10.3	2
147	Reply to Pattou et al.. <i>Hepatology</i> , 2022 ,	11.2	
146	Breakthroughs in therapies for NASH and remaining challenges.. <i>Journal of Hepatology</i> , 2022 , 76, 1263-1278	13.4	1
145	External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B 2022 , 1, 604-617		0
144	Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease.. <i>Frontiers in Nutrition</i> , 2021 , 8, 774030	6.2	1
143	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
142	EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2021 ,	13.4	6
141	Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2021 ,	13.4	5
140	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021 ,	13.3	5
139	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021 , 13, eabe8939	17.5	3
138	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021 , 385, 1547-1558	59.2	50
137	Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. <i>Journal of Hepatology</i> , 2021 ,	13.4	3

136	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	37
135	RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2021 , 70, 2359-2372	19.2	10
134	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021 , 592, 450-456	50.4	164
133	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021 , 41, 1227-1242	7.9	20
132	Yet more evidence that MAFLD is more than a name change. <i>Journal of Hepatology</i> , 2021 , 74, 977-979	13.4	8
131	European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021 , 3, 100234	10.3	13
130	Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. <i>Clinical Liver Disease</i> , 2021 , 17, 398-400	10.0	1
129	From the Editor's Desk <i>Journal of Hepatology</i> , 2021 , 74, 1277-1280	13.4	78
128	Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	8
127	Real-World Burden of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 1020-1029.e7	6.9	5
126	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021 , 384, 1113-1124	59.2	244
125	From the Editor's Desk <i>Journal of Hepatology</i> , 2021 , 74, 1-4	13.4	2
124	Liver Stiffness by Transient Elastography to Detect Porto-Sinusoidal Vascular Liver Disease With Portal Hypertension. <i>Hepatology</i> , 2021 , 74, 364-378	11.2	9
123	Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Microorganisms</i> , 2021 , 9,	4.9	10
122	coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. <i>Hepatology Communications</i> , 2021 , 5, 774-785	6	2
121	TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021 , 161, 1475-1486	13.3	13
120	External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021 , 3, 100298	10.3	3
119	Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. <i>Journal of Hepatology</i> , 2021 , 75, 1292-1300	13.4	5

118	From the Editor's Desk <i>Journal of Hepatology</i> , 2021 , 75, 257-260	13.4	78
117	Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021 , 6, 889-902	18.8	5
116	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021 , 75, 770-785	13.4	19
115	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2021 ,	13.4	7
114	From the Editor's Desk <i>Journal of Hepatology</i> , 2020 , 73, 1299-1302	13.4	
113	Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. <i>Nature Metabolism</i> , 2020 , 2, 514-531	14.6	17
112	Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. <i>Scientific Reports</i> , 2020 , 10, 3850	4.9	13
111	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 158, 1999-2014.e1	13.3	748
110	Genecriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020 , 72, 892-905	11.2	116
109	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020 , 73, 202-209	13.4	764
108	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020 , 15, e0242306	3.7	4
107	Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020 , 29, 235-245	1.4	9
106	Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. <i>Cell Reports Medicine</i> , 2020 , 1, 100154	18	8
105	A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and genecriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020 , 88, 105889	2.3	45
104	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020 , 72, 828-838	13.4	22
103	Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 998-1007	2.2	5
102	Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020 , 72, 627-635	13.4	34
101	Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. <i>Molecular Genetics and Metabolism</i> , 2020 , 129, 59-66	3.7	7

100	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020 , 97, 106174	2.3	8
99	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020 , 98, 106175	2.3	28
98	From the Editor's Desk <i>Journal of Hepatology</i> , 2020 , 73, 1001-1004	13.4	78
97	From the Editor's Desk <i>Journal of Hepatology</i> , 2020 , 73, 475-478	13.4	78
96	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
95	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020 , 5, 970-985	18.8	54
94	Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020 , 2, 1001-1003	14.2	20
93	From the Editor's Desk.... <i>Journal of Hepatology</i> , 2020 , 73, 745-748	13.4	78
92	Clinical endpoints are necessary in the interim analysis of REGENERATE - Authors' reply. <i>Lancet, The</i> , 2020 , 396, 663-664	4.0	
91	A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <i>Advances in Therapy</i> , 2020 , 37, 4627-4640	4.1	2
90	Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020 , 40, 830-845	2.5	4
89	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020 , 72, 14-24	13.4	75
88	Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 216-225.e5	6.9	46
87	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113
86	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019 , 1, 188-198	10.3	46
85	Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. <i>Transplantation</i> , 2019 , 103, 28-38	1.8	16
84	External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease. <i>GastroHep</i> , 2019 , 1, 146-153	1	2
83	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019 , 70, 1841-1855	11.2	41

82	The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019 , 70, 1913-1927	11.2	111
81	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 454-465	18.8	28
80	Relationship Among Fatty Liver, Specific and Multiple-Site Atherosclerosis, and 10-Year Framingham Score. <i>Hepatology</i> , 2019 , 69, 1453-1463	11.2	19
79	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019 , 84, 105803	2.3	72
78	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 193-203	6.1	62
77	Improving NASH with a little help from thyromimetics. <i>Lancet, The</i> , 2019 , 394, 1970-1972	4.0	1
76	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 2184-2196	4.0	425
75	The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019 , 31, 393-402	2.2	8
74	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 80, e86-e94	3.1	26
73	LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 49, 308-320	6.1	8
72	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 616-629.e26	6.9	53
71	Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018 , 42, 416-426	2.4	10
70	Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 569-577	2.2	13
69	Impact of steatosis and inflammation definitions on the performance of NASH tests. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 384-391	2.2	7
68	The painful reality of end-stage liver disease in NASH. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 8-10	18.8	3
67	Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D). <i>American Journal of Gastroenterology</i> , 2018 , 113, 443-445	0.7	2
66	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018 , 67, 2001-2012	11.2	79
65	A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018 , 67, 1754-1767	11.2	376

64	The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018 , 69, 1365-1370	13.4	29
63	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. <i>Journal of Hepatology</i> , 2018 , 69, 896-904	13.4	55 ^o
62	A critical review of endpoints for non-cirrhotic NASH therapeutic trials. <i>Journal of Hepatology</i> , 2018 , 68, 353-361	13.4	37
61	Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 1117-1127	6.1	14
60	Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018 , 155, 1140-1153	13.3	15 ⁶
59	Non-pharmacological interventions in non-alcoholic fatty liver disease patients. <i>Liver International</i> , 2017 , 37 Suppl 1, 90-96	7.9	23
58	Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity. <i>Gut</i> , 2017 , 66, 1688-1696	19.2	47
57	Screening studies of transient elastography and FibroTest in the general population. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 246	18.8	1
56	Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017 , 12, e0189436	3.7	11
55	Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017 , 112, 740-751	0.7	273
54	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016 , 3, e000075	3.9	62
53	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- α Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016 , 150, 1147-1159.e5	13.3	62 ⁹
52	Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison. <i>PLoS ONE</i> , 2016 , 11, e0163276	3.7	24
51	Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2016 , 25, 183-9	1.4	4
50	Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 428-327	2.7	15
49	Arterial hypertension as an uninvited player in hepatic stiffness?. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, G942-G944	5.1	3
48	How to best diagnose NAFLD/NASH? 2016 , 111-123		
47	Novel Pharmacotherapy Options for NASH. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 1398-405	4	27

46	Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. <i>Contemporary Clinical Trials</i> , 2016 , 47, 356-65 ^{2,3}	142
45	Fatty liver is an independent predictor of early carotid atherosclerosis. <i>Journal of Hepatology</i> , 2016 , 65, 95-102	13.4 67
44	NAFLD and liver transplantation: Current burden and expected challenges. <i>Journal of Hepatology</i> , 2016 , 65, 1245-1257	13.4 237
43	Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease". <i>Journal of Hepatology</i> , 2016 , 65, 1267-1268	13.4 2
42	Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. <i>Hepatology</i> , 2015 , 61, 1041-55	11.2 81
41	Current efforts and trends in the treatment of NASH. <i>Journal of Hepatology</i> , 2015 , 62, S65-75	13.4 185
40	Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 763-71.e1-6	6.9 46
39	Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 992-9.e2	6.9 18
38	Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). <i>Lancet Infectious Diseases</i> , 2015 , 15, 397-404	25.5 244
37	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. <i>Future Oncology</i> , 2015 , 11, 2553-62	3.6 12
36	Starting the battle to control non-alcoholic steatohepatitis. <i>Lancet</i> , 2015 , 385, 922-4	40 11
35	Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. <i>Hepatology</i> , 2015 , 61, 41-5	11.2 136
34	Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. <i>BMJ Open</i> , 2015 , 5, e010017	3 9
33	Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2015 , 26, 30-6	3.9 30
32	Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. <i>PLoS ONE</i> , 2015 , 10, e0134302	3.7 9
31	Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. <i>World Journal of Gastroenterology</i> , 2015 , 21, 5647-53	5.6 10
30	Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014 , 61, 1220-7	13.4 24
29	Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest [®]) and elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014 , 61, 994-1003	13.4 36

28	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014 , 5, 4309	17.4	362
27	The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. <i>Clinics in Liver Disease</i> , 2014 , 18, 165-78	4.6	26
26	Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini?". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014 , 38, 432-9	2.4	9
25	Targeting non-alcoholic fatty liver disease through 11-βSD1 inhibition. <i>Lancet Diabetes and Endocrinology</i> , 2014 , 2, 354-6	18.1	2
24	Non-alcoholic fatty liver disease: diagnosis and investigation. <i>Digestive Diseases</i> , 2014 , 32, 586-96	3.2	8
23	SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3429-36	5.9	13
22	Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage. <i>Hepatology Research</i> , 2014 , 44, 1241-1247	5.1	13
21	Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest) and transient elastography (FibroScan). <i>Journal of Hepatology</i> , 2014 , 60, 706-14	13.4	85
20	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013 , 58, 1941-52	11.2	279
19	Pharmacological agents for NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013 , 10, 676-85	24.2	52
18	Pharmacological agents for nonalcoholic steatohepatitis. <i>Hepatology International</i> , 2013 , 7 Suppl 2, 833-838	8.8	2
17	Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. <i>Journal of Infectious Diseases</i> , 2013 , 208, 1000-7	7	23
16	From NAFLD in clinical practice to answers from guidelines. <i>Journal of Hepatology</i> , 2013 , 59, 859-71	13.4	249
15	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2013 , 59, 550-6	13.4	326
14	Anti-hepatitis C virus antibody detection in oral fluid: influence of human immunodeficiency virus co-infection. <i>Journal of Clinical Virology</i> , 2013 , 58, 385-90	14.5	10
13	Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2013 , 59, 675-83	13.4	115
12	Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. <i>Journal of Hepatology</i> , 2013 , 58, 928-35	13.4	129
11	Is mipomersen ready for clinical implementation? A transatlantic dilemma. <i>Current Opinion in Lipidology</i> , 2013 , 24, 301-6	4.4	18

10	Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. <i>Annals of Internal Medicine</i> , 2013 , 159, 370-1	8	1
9	Randomized study of asunaprevir plus pegylated interferon- α and ribavirin for previously untreated genotype 1 chronic hepatitis C. <i>Antiviral Therapy</i> , 2013 , 18, 885-93	1.6	43
8	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. <i>World Journal of Gastroenterology</i> , 2013 , 19, 57-64	5.6	77
7	Treatment of NASH with ursodeoxycholic acid: pro. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012 , 36 Suppl 1, S41-5	2.4	18
6	Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. <i>Journal of Hepatology</i> , 2012 , 57, 541-8	13.4	52
5	Performances of Elasto-FibroTest(\square), a combination between FibroTest(\square) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012 , 36, 455-63	2.4	12
4	Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. <i>BMC Gastroenterology</i> , 2011 , 11, 39	3	53
3	Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006 , 6, 6	3	304
2	Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. <i>Lancet, The</i> , 2001 , 357, 1069-75	40	1136
1	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease		1